Launched in 2017, the UK DRI stands as a beacon of scientific innovation, representing an unprecedented £300 million investment in dementia research—the largest of its kind in UK history. The purpose of the UK DRI is to transform the outlook for people living with or at risk of neurodegenerative conditions through research.
Applications are invited for a Research Associate in oligodendrocyte and neuroimmune epigenomics to join the lab of Dr Alexi Nott (https://nottgroup.com/index.html ) in the UK DRI at Imperial.
Following a new collaborative UK DRI Key Questions Award with Dr Sarah Marzi (King's), Dr Rikesh Rajani (Edinburgh), and Dr Dervis Salih (UCL), we are seeking to appoint a dynamic postdoctoral researcher to lead one or more projects to characterise the epigenome of oligodendrocytes and neuroimmune cell types in early Alzheimer's and resilience to dementia using patient-derived samples. This post is funded for three years: the first 1.5 years based at Imperial on the White City Campus under the guidance of Dr Alexi Nott, where you will profile the epigenome of brain-derived oligodendrocytes and neuroimmune cell types. The second phase of the project will be in the lab of Dr Sarah Marzi, at the Denmark Hill Campus of King's College London, to examine the epigenome of macroglia at single-cell resolution. You will contribute to the design and generation of large-scale 'omics datasets with a primary focus on epigenomic analysis at cell-type-enriched and single-nuclei resolution to address major research questions relevant to Alzheimer's and resilience to dementia.
#J-18808-Ljbffr